Management of toxicities of immune checkpoint inhibitors. (March 2016)

• Record Type: Journal Article
• Authors: Spain, Lavinia; Diem, Stefan; Larkin, James
• Is Part Of: Cancer treatment reviews. Volume 44(2016)
• Page Start: 51
• Page End: 60
• Publication Date: 2016-03
• Subjects: Immune-checkpoint inhibitors -- Immune-related adverse events -- Ipilimumab -- Nivolumab -- Pembrolizumab -- Melanoma -- Lung cancer -- Renal cancer; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2016.02.001
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: Role of immune checkpoint inhibition in the management of key malignancies. Description of rates of immune-related adverse events and timing of their onset. Management strategies for immune-related toxicities. Abstract: Immune checkpoint inhibition with the anti-CTLA-4 antibody ipilimumab and the anti-PD-1 antibodies nivolumab and pembrolizumab has improved survival in metastatic melanoma, lung cancer and renal cancer. Use of these agents holds promise in other malignancies. The augmented immune response enabled by these agents has led to a particular group of side effects called immune-related adverse events (irAEs). The main irAEs include diarrhea, colitis, hepatitis, skin toxicities and endocrinopathies such as hypophysitis and thyroid dysfunction. The anti-PD-1 antibodies have a different toxicity profile to ipilimumab with fewer high grade events. This article identifies the rates of common and uncommon irAEs associated with each immune checkpoint inhibitor (ICPI) and their timing of onset, focusing mainly on the experience in melanoma and lung cancer. An approach to management for each class of irAE is provided.